CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Kelvin P. Lee

CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival

Multiple myeloma and immunoproliferative diseases

Ping Xie

Molecular mechanisms of B cell malignant transformation

Multiple myeloma and immunoproliferative diseases

Teru Hideshima

Functional and biologic significance of deacetylase3 inhibition in myeloma

Multiple myeloma and immunoproliferative diseases

Ralph D Sanderson

Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies

Jetze J Tepe

Characterization of Non-Competitive Proteasome Binding

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Clark W Distelhorst

Bcl-2 Function on the Endoplasmic Reticulum

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Catriona HM Jamieson

(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Elad Ziv

Influence of germ line genetic variation on myeloma progression and survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Conor C Lynch

Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology